Chlamydia pneumoniae serology: Comparing a commercial enzyme immunoassay and microimmunofluorescence test in patients with cardiovascular disease

APMIS

Volumn 111, Issue 2, 2003, Pages 363-369

  Vainas, Tryfon ^a,b   De Graaf, Rick ^a   Stassen, Frank R M ^a   Kurvers, Harrie A J M ^a   Grauls, Gert E L M ^a   Kitslaar, Peter J E H M ^a   Bruggeman, Cathrien A ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Atherosclerosis; Chlamydia pneumoniae; Enzyme immunoassay; Microimmunofluorescence; Serology

Indexed keywords

BACTERIUM ANTIBODY; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G;

ANTIBODY DETECTION; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME IMMUNOASSAY; HUMAN; IMMUNOFLUORESCENCE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZATION; SERODIAGNOSIS;

ANTIBODIES, BACTERIAL; CARDIOVASCULAR DISEASES; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN G; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0037542521     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0463.2003.1110210.x     Document Type: Article

References (14)

1. Grayston JT Does Chlamydia pneumoniae cause atherosclerosis? Arch Surg 1999;134:930-4.
2. Siscovick DS, Schwartz SM, Caps M, Wang SP, Grayston JT Chlamydia pneumoniae and atherosclerotic risk in populations: the role of seroepidemiology. J Infect Dis 2000;181 Suppl 3: S417-20.
3. Dowell SF, Peeling RW, Boman J, Carlone GM, Fields BS, Guarner J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001; 33:492-503.
4. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-6.
5. Grayston JT, Kuo CC, Wang SP, Altman J. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986;315:161-8.
6. Kauppinen M, Saikku P. Pneumonia due to Chlamydia pneumoniae: prevalence, clinical features, diagnosis, and treatment. Clin Infect Dis 1995;21 Suppl 3:S244-52.
7. Numazaki K, Ikebe T, Chiba S. Detection of serum antibodies against Chlamydia pneumoniae by ELISA. FEMS Immunol Med Microbiol 1996;14:179-83.
8. Schumacher A, Lerkerod AB, Seljeflot I, Sommervoll L, Holme I, Otterstad JE, et al. Chlamydia pneumoniae serology: importance of methodology in patients with coronary heart disease and healthy individuals. J Clin Microbiol 2001;39: 1859-64.
9. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
10. Tuuminen T, Varjo S, Ingman H, Weber T, Oksi J, Viljanen M. Prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae immunoglobulin G and A antibodies in a healthy Finnish population as analyzed by quantitative enzyme immunoassays. Clin Diagn Lab Immunol 2000;7: 734-8.
11. Boman J, Hammerschlag MR. Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies. Clin Microbiol Rev 2002;15:1-20.
12. Tuuminen T, Palomaki P, Paavonen J. The use of serologic tests for the diagnosis of chlamydial infections. J Microbiol Methods 2000;42:265-79.
13. Peeling RW, Wang SP, Grayston JT, Blasi F, Boman J, Clad A, et al. Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results. J Infect Dis 2000;Suppl 3:S426-9.
14. Gnarpe J, Naas J, Lundback A. Comparison of a new commercial EIA kit and the microimmunofluorescence technique for the determination of IgG and IgA antibodies to Chlamydia pneumoniae. APMIS 2000;108:819-24.